577 related articles for article (PubMed ID: 24625244)
1. Burden of venous leg ulcers in the United States.
Rice JB; Desai U; Cummings AK; Birnbaum HG; Skornicki M; Parsons N
J Med Econ; 2014 May; 17(5):347-56. PubMed ID: 24625244
[TBL] [Abstract][Full Text] [Related]
2. Direct and indirect healthcare resource utilization and costs associated with ulcerative colitis in a privately-insured employed population in the US.
Cohen R; Skup M; Ozbay AB; Rizzo J; Yang M; Diener M; Chao J
J Med Econ; 2015 Jun; 18(6):447-56. PubMed ID: 25728698
[TBL] [Abstract][Full Text] [Related]
3. Direct and indirect costs associated with epileptic partial onset seizures among the privately insured in the United States.
Ivanova JI; Birnbaum HG; Kidolezi Y; Qiu Y; Mallett D; Caleo S
Epilepsia; 2010 May; 51(5):838-44. PubMed ID: 20002150
[TBL] [Abstract][Full Text] [Related]
4. Economic burden of sarcoidosis in a commercially-insured population in the United States.
Rice JB; White A; Lopez A; Conway A; Wagh A; Nelson WW; Philbin M; Wan GJ
J Med Econ; 2017 Oct; 20(10):1048-1055. PubMed ID: 28678623
[TBL] [Abstract][Full Text] [Related]
5. Healthcare resource utilization and work loss in dermatomyositis and polymyositis patients in a privately-insured US population.
Bradford Rice J; White A; Lopez A; Galebach P; Schepman P; Popelar B; Philbin M
J Med Econ; 2016 Jul; 19(7):649-54. PubMed ID: 26850074
[TBL] [Abstract][Full Text] [Related]
6. Direct and indirect costs associated with Dupuytren's contracture.
Macaulay D; Ivanova J; Birnbaum H; Sorg R; Skodny P
J Med Econ; 2012; 15(4):664-71. PubMed ID: 22369346
[TBL] [Abstract][Full Text] [Related]
7. Direct and indirect costs of non-vertebral fracture patients with osteoporosis in the US.
Pike C; Birnbaum HG; Schiller M; Sharma H; Burge R; Edgell ET
Pharmacoeconomics; 2010; 28(5):395-409. PubMed ID: 20402541
[TBL] [Abstract][Full Text] [Related]
8. The economic burden of brain metastasis among lung cancer patients in the United States.
Guérin A; Sasane M; Dea K; Zhang J; Culver K; Nitulescu R; Wu EQ; Macalalad AR
J Med Econ; 2016; 19(5):526-36. PubMed ID: 26735844
[TBL] [Abstract][Full Text] [Related]
9. Burden of diabetic foot ulcers for medicare and private insurers.
Rice JB; Desai U; Cummings AK; Birnbaum HG; Skornicki M; Parsons NB
Diabetes Care; 2014; 37(3):651-8. PubMed ID: 24186882
[TBL] [Abstract][Full Text] [Related]
10. Analysis of buprenorphine/naloxone dosing impact on treatment duration, resource use and costs in the treatment of opioid-dependent adults: a retrospective study of US public and private health care claims.
Khemiri A; Kharitonova E; Zah V; Ruby J; Toumi M
Postgrad Med; 2014 Sep; 126(5):113-20. PubMed ID: 25295655
[TBL] [Abstract][Full Text] [Related]
11. The economic burden of major adult visual disorders in the United States.
Rein DB; Zhang P; Wirth KE; Lee PP; Hoerger TJ; McCall N; Klein R; Tielsch JM; Vijan S; Saaddine J
Arch Ophthalmol; 2006 Dec; 124(12):1754-60. PubMed ID: 17159036
[TBL] [Abstract][Full Text] [Related]
12. Medicare patient experience with vagus nerve stimulation for treatment-resistant depression.
Feldman RL; Dunner DL; Muller JS; Stone DA
J Med Econ; 2013; 16(1):62-74. PubMed ID: 22954061
[TBL] [Abstract][Full Text] [Related]
13. Healthcare utilization and costs of patients with rosacea in an insured population.
Romanowicz M; Stephenson JJ; Del Rosso JQ; Lenhart G
J Drugs Dermatol; 2008 Jan; 7(1):41-9. PubMed ID: 18246697
[TBL] [Abstract][Full Text] [Related]
14. Incremental health care resource utilization and economic burden of venous thromboembolism recurrence from a U.S. payer perspective.
Lin J; Lingohr-Smith M; Kwong WJ
J Manag Care Pharm; 2014 Feb; 20(2):174-86. PubMed ID: 24456319
[TBL] [Abstract][Full Text] [Related]
15. Clinical comorbidities, treatment patterns, and direct medical costs of patients with osteoarthritis in usual care: a retrospective claims database analysis.
Gore M; Tai KS; Sadosky A; Leslie D; Stacey BR
J Med Econ; 2011; 14(4):497-507. PubMed ID: 21682606
[TBL] [Abstract][Full Text] [Related]
16. The economic burden of psoriasis with high comorbidity among privately insured patients in the United States.
Pilon D; Teeple A; Zhdanava M; Ladouceur M; Ching Cheung H; Muser E; Lefebvre P
J Med Econ; 2019 Feb; 22(2):196-203. PubMed ID: 30523738
[TBL] [Abstract][Full Text] [Related]
17. Costs and quality of life of multiple sclerosis in Austria.
Kobelt G; Berg J; Lindgren P; Plesnilla C; Baumhackl U; Berger T; Kolleger H; Vass K
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S14-23. PubMed ID: 17310339
[TBL] [Abstract][Full Text] [Related]
18. Economic burden of non-cystic fibrosis bronchiectasis in the first year after diagnosis from a US health plan perspective.
Joish VN; Spilsbury-Cantalupo M; Operschall E; Luong B; Boklage S
Appl Health Econ Health Policy; 2013 Jun; 11(3):299-304. PubMed ID: 23580074
[TBL] [Abstract][Full Text] [Related]
19. Healthcare resource use and costs of privately insured patients who switch, discontinue, or persist on anti-muscarinic therapy for overactive bladder.
Ivanova JI; Hayes-Larson E; Sorg RA; Birnbaum HG; Berner T
J Med Econ; 2014 Oct; 17(10):741-50. PubMed ID: 25051328
[TBL] [Abstract][Full Text] [Related]
20. Healthcare cost attributable to recently-diagnosed breast cancer in a privately-insured population in the United States.
Fu AZ; Jhaveri M
J Med Econ; 2012; 15(4):688-94. PubMed ID: 22397589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
